ABT Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.…
Industry Peers
Medical DevicesKey Statistics
About Abbott Laboratories (NYSE: ABT)
›
Abbott Laboratories (NYSE: ABT) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 122,000 employees.
The shares were at 103.97 USD on 19 November 2026, down 15.8% over 52 weeks. Its 52-week range is 81.97 USD to 132.03 USD: the price is 21.3% below the high and 26.8% above the low.
At a market capitalisation of 179.90B USD, it trades at 38.8 times trailing earnings and 17.5 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.4, a premium of 52% for ABT. It pays a dividend yielding 2.41% (it pays out 93% of its earnings), against a median of 2.31% among the dividend payers in that peer group.
Abbott Laboratories reports return on equity of 12.5%, an operating margin of 15.6% and revenue up 14.5% year over year.
Its debt exceeds its cash by 27.14B USD, a debt-to-equity ratio of 0.27. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 118.91 USD is 14.4% above the current price. The next earnings report is expected on 28 January 2027.